Table 3.
Proportion of patients with chronic kidney disease receiving apixaban who experienced thrombotic events
| Outcome | 5 mg BID | 2.5 mg BID | P valuea | 10 mg BID |
|---|---|---|---|---|
| (n = 22) | (n = 73) | (n = 3) | ||
| Ischemic stroke | 0 | 2 (3%) | 1.00 | 0 |
| Venous thromboembolism | 1 (5%) | 0 | 0.23 | 0 |
For comparison between 5.0 and 2.5 mg BID doses.